Home » Topics » New compound, BioWorld Science

New compound, BioWorld Science
RSS

Abbott evaluating clitocine analogues

Sep. 6, 1996

Abbott describes immunosuppressants

Sep. 6, 1996

HIV protease inhibitor under evaluation at Pharmacia & Upjohn

Sep. 6, 1996

Merck & Co. describes antibiotics active against resistant staphylococci

Sep. 6, 1996

NPC-18521, a high-affinity bradykinin B2 receptor antagonist from Scios

Sep. 6, 1996

NSC-665158: HIV-1 reverse transcriptase inhibitor analogue

Aug. 30, 1996

Merck & Co. reports on L-163689

Aug. 30, 1996

Yamanouchi reveals 5HT3 agonist

Aug. 30, 1996

Endothelin converting enzyme inhibitor revealed by Schering-Plough

Aug. 30, 1996

Lilly's new AMPA antagonist, LY-311446

Aug. 30, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 14, 2025.
European VCs optimistic for med-tech exit opportunities in 2025
BioWorld MedTech
To say that European investors are optimistic about the outlook for the med-tech sector in 2025 is an understatement. A couple of companies are already listed on...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for February 14, 2025
European VCs bullish on med-tech investments in 2025
BioWorld MedTech
European companies looking for capital should find the fundraising environment more favorable in 2025. Private med-tech financings in January totaled about $2...
Kura/Kyowa Kirin’s ziftomenib hits phase II endpoints in AML
BioWorld
Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the phase II registrational Komet-001 trial...